IPXL - Impax Laboratories, Inc.

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (3Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • A Performance Overview of Merck’s Cardiovascular Segment
    Market Realist9 months ago

    A Performance Overview of Merck’s Cardiovascular Segment

    Merck & Co.’s (MRK) Zetia generated revenues of $165 million in the third quarter, reflecting a ~48% YoY (year-over-year) decline and a ~27% sequential decline. Zetia reported net revenues of $696 million in the first nine months of the year compared to $1 billion in the same period of 2017, reflecting a ~32% YoY decline.

  • How Is Merck’s Cardiovascular Portfolio Positioned after H1 2018?
    Market Realistlast year

    How Is Merck’s Cardiovascular Portfolio Positioned after H1 2018?

    In the second quarter of 2018, Merck’s (MRK) Zetia generated revenues of $226.0 million compared to $367.0 million in the second quarter of 2017, reflecting a ~38% year-over-year (or YoY) decline and a ~26% sequential decline. In the second quarter of 2018, in the US and international markets (outside the US markets), Zetia generated revenues of $8.0 million and $218.0 million, respectively, compared to $122.0 million and $246.0 million in the second quarter of 2017.

  • We're sorry this is all we were able to find about this topic.